Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15212


Purpose:

The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass


Study summary:

Dialysis patients have significant morbidity and mortality associated with left ventricular hypertrophy and cardiac failure. Aldosterone may have an important role in the development of myocardial hypertrophy and remodeling. Animal studies have demonstrated beneficial effects of aldosterone antagonists on myocardial hypertrophy, and human studies have shown significant survival benefit in a non-dialysis population with congestive heart failure. This study evaluates the effect of spironolactone (an aldosterone receptor antagonist) on cardiac hypertrophy in the end-stage renal disease population.


Criteria:

Inclusion Criteria: - hemodialysis patients Exclusion Criteria: - non compliance - hyperkalemia - pregnancy - expected survival less than 9 months


NCT ID:

NCT00548912


Primary Contact:

Principal Investigator
Richard Marcus
West Penn Allegheny Health System


Backup Contact:

N/A


Location Contact:

Pittsburgh, Pennsylvania 15212
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.